Gamma irradiation reduces the immunological toxicity of doxorubicin, anticancer drug.
- Authors
- Jae-Hun Kim; Nak-Yun Sung; H. Balaji Raghavendran; Yoon, Yo Han; Beom-Seok Song; Jong-il Choi; Young-Choon Yoo; Myung-Woo Byun; Young-Jeong Hwang; Ju-Woon Lee
- Issue Date
- Jul-2009
- Publisher
- PERGAMON-ELSEVIER SCIENCE LTD
- Citation
- RADIATION PHYSICS AND CHEMISTRY, v.78, no.7-8, pp 425 - 428
- Pages
- 4
- Journal Title
- RADIATION PHYSICS AND CHEMISTRY
- Volume
- 78
- Number
- 7-8
- Start Page
- 425
- End Page
- 428
- URI
- https://scholarworks.sookmyung.ac.kr/handle/2020.sw.sookmyung/148086
- DOI
- 10.1016/j.radphyschem.2009.03.020
- ISSN
- 0969-806X
- Abstract
- Doxorubicin (DOX) is a widely used anticancer agent, but exhibits some immunological toxicity to patients during chemotherapy. The present study was conducted to evaluate the effect of gamma irradiation on the immunological response and the inhibition activity on in vivo tumor mass of DOX. The results showed that DOX irradiated at 10 and 20 kGy reduce the inhibition of mouse peritoneal macrophage proliferation and induce the release of cytokines (TNF-α and IL-6) when compared with non-irradiated DOX. The cytotoxicity against human breast (MCF-7), murine colon adenocarcinoma (Colon 26) and human monocytic (THP-1) tumor cell were not significantly different between non-irradiated and irradiated DOX (P<0.05). In vivo study on the tumor mass inhibition, gamma-irradiated DOX showed a considerable inhibition of tumor mass and this effect was statistically non-significant as compared with non-irradiated DOX. In conclusion, gamma irradiation could be regarded as a potential method for reducing the immunological toxicity of DOX. Further researches is needed to reveal the formation and activity of radiolysis products by gamma irradiation.
- Files in This Item
-
Go to Link
- Appears in
Collections - 생활과학대학 > 식품영양학과 > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.